Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan notifications rather than financial performance results.
Material Changes
On April 18, 2012, the Administrators of the GlaxoSmithKline Performance Share Plan notified the Company of an increase in notional interests in Ordinary Shares for specific participants. This increase resulted from the notional re-investment of the dividend paid to shareholders on April 12, 2012, at a price of 1420 per Ordinary Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors
- The filing reports a notional share price of 1420 per Ordinary Share used for dividend re-investment on April 12, 2012.
- Notional interest increases were recorded for Mr P Thomson (63.879 shares), Dr P J T Vallance (770.332 shares), Mr C Weber (339.988 shares), and Mrs V A Whyte (63.879 shares).
- Actual payout of accrued notional dividends is contingent upon the vesting of Performance Share Plan holdings after a three-year measurement period.
- This report does not contain financial statements or operational results for the period.